NCT01146795 Clinical Trial Information | SourceSolution's Biotech, Pharma, CMO, CRO Directory

Neoadjuvant for Ovarian Cancer


Sponsors: Columbia University Genentech	Phases: Phase II
Indications	Acronym:
Epithelial Ovarian Cancer Primary Peritoneal Cancer Fallopian Tube Cancer
Age Groups: Adult Senior	Gender: Female
Names: Drug: Carboplatin, paclitaxel, and bevacizumab	Enrollment: 45

Additional information about NCT01146795.